Behavioral Health: Individual Psychotherapy
Number: 1106
Table Of Contents
PolicyApplicable CPT / HCPCS / ICD-10 Codes
Background
References
Policy
Scope of Policy
This Clinical Policy Bulletin addresses behavioral health individual psychotherapy.
-
Medical Necessity
Subject to applicable benefit plan terms and limitations, Aetna considers individual psychotherapy a medically necessary behavioral health service for the diagnosis, evaluation, and treatment of a mental health disorder or substance use disorder (SUD) when the condition causes clinically significant distress and/or functional impairment and when all of the criteria below are met. Note: Treatment should be individualized, use evidence-based psychotherapy interventions, include measurable treatment goals, and demonstrate ongoing progress and/or modified treatment planning through active reassessment to improve symptoms, functioning, and quality of life. See Appendix for additional information.
- The services are ordered by a physician or independently licensed behavioral health professional (BHP) (e.g., psychiatrist, psychologist, psychiatric-mental health nurse practitioner [PMHNP], physician associate [PA], social worker [LCSW], marriage and family therapist [LMFT] or professional counselor [LPC]) licensed to practice without supervision in their State and are directly related to an active treatment plan of care established by the physician or licensed BHP; and
- The member carries a diagnosis from the current iteration of the Diagnostic and Statistical Manual (DSM) of a mental health/substance use disorder that is appropriate for individual-based intervention (e.g., depressive disorders, anxiety disorders, trauma- related disorders, substance use disorders, personality disorders, etc.); and
- The diagnosis and need for treatment are established through a documented comprehensive behavioral health evaluation performed by a physician or licensed BHP; and
- Member can participate safely in a structured therapeutic session; and
- The therapeutic modality must be matched and adapted to cognitive level and member’s specific needs; and
- Individual psychotherapy meets all of the following program requirements:
- Individual psychotherapy is the provision of psychotherapy services to one member by one licensed or supervised behavioral health practitioner during the treatment session. The service does not include family, couples, or group psychotherapy; and
- Individual Psychotherapy is conducted by or under the direct supervision of a clinician licensed and trained to deliver psychotherapy within scope of practice (e.g., psychologist, LCSW, LPC, LMFT, PMHNP, PA, MD/DO); and
- A licensed supervisor may only supervise a maximum of six supervisees in the provision of individual psychotherapy; and
- Psychotherapy Current Procedural Terminology (CPT) codes are payable only to practitioners for whom psychotherapy is within scope of practice, without a categorical prohibition on other providers' participation in behavioral care; and
- Psychotherapy is based on evidence-based practices tailored to the specific needs and behavioral health diagnoses of the member (e.g., depressive disorders, substance use disorders, trauma, anxiety); and
- High-quality psychotherapy should include the following core components:
-
Comprehensive evaluation/assessment
- Diagnostic evaluation using the current iteration of the DSM criteria
- Assessment of symptom severity
- Functional assessment
- Psychosocial history
- Medical and psychiatric history
- Substance use assessment
- Trauma history, when clinically indicated
- Suicide and violence risk assessment
- Cultural, linguistic, and social determinants of health considerations; and
-
An individualized treatment plan that should:
- Delineate the primary diagnosis and contributing factors
- Establish measurable, individualized treatment goals
- Identify evidence-based interventions
- Specify treatment frequency and anticipated duration
- Include member participation and informed consent
- Be updated regularly based on clinical progress; and
-
Evidence-based interventions:
Treatment should employ interventions supported by current clinical evidence and appropriate for the member’s diagnosis and clinical presentation; and
-
Ongoing measurement and monitoring:
- Symptom improvement
- Functional improvement
- Treatment adherence
- Member engagement
- Safety concerns
- Goal attainment; and
-
Documentation (see Appendix)
-
Should include:
- Presenting/current symptoms
- Mental status examination, at intake and when clinically indicated
- Interventions utilized
- Member response
- Progress toward treatment goals
- Risk assessment, when indicated
- Plan for subsequent treatment
-
"Homework" or between session plans, as indicated;
-
- Use of validated measurement tools (e.g., PHQ-9, GAD-7, PCL-5, or other condition-specific instruments);
- Length of session in minutes;
- Date and time of session;
- Signature and credentials of psychotherapy provider
-
Supervisor signature if provider is unlicensed; and
-
- Documentation should support the duration and intensity of the billed service; and
- Documentation for Evaluation and Management (E/M) billing and individual psychotherapy billing must be maintained as separate entities with distinct documentation that accurately reflects the nature of the services provided, the clinical rationale for treatment, and the specific interventions utilized during the session, and length of session (specifically for psychotherapy services).
-
-
-
Policy Limitations and Exclusions
Coverage may vary according to the member's benefit plan. Please check benefit plan descriptions for details.
-
Related Policies
- CPB 0132 - Biofeedback
- CPB 0214 - Cognitive Rehabilitation
- CPB 0237 - Chronic Pain Rehabilitation Programs
- CPB 0256 - Sensory and Auditory Integration Therapy
- CPB 0370 - Phototherapy for Psychiatric Disorders
- CPB 0426 - Attention Deficit/Hyperactivity Disorder
- CPB 0480 - Tourette's Syndrome
- CPB 0511 - Eating Disorders
- CPB 0648 - Autism Spectrum Disorders
- CPB 0730 - Home Behavioral Healthcare Services
- CPB 0999 - Prescription Digital Therapeutics
- CPB 1100 - Behavioral Health: Group Psychotherapy
Background
Individual psychotherapy, often referred to simply as therapy or counseling, is a form of treatment in which a person works one-on-one with a trained and licensed mental health professional to address emotional, psychological, substance use, and/or behavioral issues. Its primary function is to diagnose, evaluate, and treat various mental health disorders that lead to significant distress or functional impairment in an individual's life. The overarching goal of individual psychotherapy is to enhance the client's emotional well-being, improve their coping strategies, and facilitate personal growth. By providing a safe and confidential environment, therapists help clients explore their thoughts, feelings, and behaviors, ultimately guiding them toward a better understanding of themselves and their challenges.
There are several common modalities of individual psychotherapy, each with its unique approach and techniques. Cognitive Behavioral Therapy (CBT) focuses on identifying and changing negative thought patterns and behaviors, making it effective for conditions such as anxiety and depression. Dialectical Behavior Therapy (DBT), originally developed for borderline personality disorder, emphasizes the balance between acceptance and change, incorporating skills training in areas like emotional regulation and interpersonal effectiveness. Other modalities include Interpersonal Psychotherapy (IPT), which addresses interpersonal relationships and their impact on mental health, and Psychodynamic Therapy, which explores unconscious processes and past experiences to understand current behavior. Each of these approaches is tailored to meet the specific needs of the client, ensuring a personalized therapeutic experience.
The evidence base for individual psychotherapy is robust, with numerous studies demonstrating its effectiveness in treating a wide range of mental health disorders. Research has shown that evidence-based therapies, such as CBT and DBT, lead to significant improvements in symptoms and overall functioning. Meta-analyses and systematic reviews consistently support the efficacy of psychotherapy in reducing symptoms of depression, anxiety, and trauma-related disorders. Furthermore, the integration of ongoing measurement and assessment within therapy sessions enhances treatment outcomes by allowing for adjustments based on the client's progress. This evidence-based approach not only validates the therapeutic process but also underscores the importance of individualized treatment plans that are responsive to the client's evolving needs.
Individual psychotherapy serves as a vital component of mental health care, providing a framework for understanding and addressing emotional and psychological challenges. Through various evidence-based modalities, therapists work collaboratively with clients to foster insight, resilience, and improved quality of life. The strong evidence supporting the effectiveness of these therapeutic approaches reinforces their role in promoting mental health and well-being across diverse populations.
Additionally, individual psychotherapy can be viewed as a process of meaning-making, where patients and therapists collaboratively construct and reconstruct meanings related to the patients’ experiences, emotions, and challenges. There are a number of evidence-based modalities and therapeutic approaches that emphasize meaning and can help patients find purpose and coherence in their lives. Utilizing an effective individual psychotherapy modality can lead to broader understanding, deeper insights, and more effective therapeutic outcomes, ultimately enhancing the overall effectiveness of psychotherapy and the health of the patient.
Ultimately, individual psychotherapy is used to improve behavioral health outcomes through evidence-based interventions that address diagnosable mental health conditions, functional impairment, and symptom reduction. Covered services must be medically necessary, provided by appropriately licensed practitioners, and delivered in accordance with generally accepted standards of clinical practice.
Individual therapy is a highly personalized approach to mental health treatment, designed to meet the unique needs, concerns, and goals of each client. This tailored method ensures that therapy is relevant and effective, allowing individuals to engage deeply with their specific issues. Confidentiality is a cornerstone of this therapeutic process, as it creates a safe space for clients to discuss sensitive topics without fear of judgment or disclosure. This privacy fosters trust, which is essential for building a strong therapeutic relationship between the therapist and the client. A robust therapeutic alliance enhances the effectiveness of therapy, as clients are more likely to open up and explore difficult emotions when they feel supported and understood.
Moreover, therapists employ a variety of techniques to address the diverse challenges faced by clients. These techniques may include cognitive-behavioral therapy (CBT), which focuses on changing negative thought patterns; dialectical-behavioral therapy (DBT), which emphasizes emotional regulation and interpersonal effectiveness; and psychodynamic therapy, which explores unconscious processes and past experiences. Other approaches, such as Eye Movement Desensitization and Reprocessing (EMDR), are also utilized, particularly for trauma-related issues. By integrating multiple therapeutic modalities, therapists can adapt their strategies to best suit the individual’s circumstances, ultimately leading to more effective treatment outcomes. This comprehensive and flexible approach to therapy not only addresses immediate concerns but also promotes long-term mental health and well-being.
The Efficacy and Structure of Time-Based Psychotherapy
Time-based psychotherapy, particularly in the context of short-term therapy, has garnered moderate evidence supporting its effectiveness for common mental health conditions such as depression and anxiety. While the overall evidence comparing shorter versus longer durations remains limited and somewhat mixed, key findings indicate that short-term therapy can yield meaningful and rapid gains. A systematic review and meta-analysis of 19 randomized controlled trials (RCTs) involving 3,447 participants found no significant differences in anxiety symptoms or functioning between shorter and longer-term psychotherapy, although the studies were at high risk of bias and the certainty of evidence was low. Notably, some adequately powered trials showed no difference in outcomes between varying lengths of therapy, such as 6 versus 12 months of Dialectical Behavior Therapy (DBT) or 20 weeks versus 3 years of psychodynamic psychotherapy.
Short-term therapies are also recognized for their cost-effectiveness. For instance, the Helsinki Psychotherapy Study randomized patients with mood or anxiety disorders to different therapy durations and found that short-term therapies produced faster improvements in psychosocial functioning and quality of life within the first year. Although long-term therapy showed small advantages in symptoms and work ability at a 10-year follow-up, these benefits were partly attributed to higher rates of auxiliary treatment in the short-term groups. Importantly, long-term therapy was not cost-effective compared to short-term options due to significantly higher direct costs.
Dose-response data further support the efficacy of defined treatment courses. A large study involving over 102,000 patients indicated that a majority of treatment responders achieved reliable and clinically significant improvement within a limited number of sessions—7 sessions for low-intensity Cognitive Behavioral Therapy (CBT) and 14 sessions for high-intensity CBT. However, conditions like PTSD, OCD, and social anxiety disorder may require longer treatment durations. Qualitative evidence suggests that the time limitation inherent in short-term therapy can enhance the therapeutic process by structuring sessions, motivating patients, and clarifying expectations.
In clinical practice, time-limited psychotherapy is well-supported for first-episode moderate depression and anxiety, with recommendations for a course of 8 to 16 sessions of evidence-based therapy. For patients with recurrent or chronic conditions, longer-term therapy may be warranted. The tapering and discontinuation of therapy should involve discussions about relapse warning signs and follow-up plans, ensuring that patients are adequately prepared for the transition. Overall, time-based psychotherapy offers a viable and effective approach to treating common mental health issues while balancing cost and therapeutic outcomes.
Individual Psychotherapy Effectiveness
The evidence base for individual psychotherapy across mental health and substance use disorders is extensive, and this section is not exhaustive. Recent or seminal evidence for individual therapy and specific diagnoses is listed below:
Anxiety Disorders
Cognitive behavioral therapy (CBT) has one of the most robust and extensively studied evidence bases among psychotherapeutic interventions for anxiety disorders.
A comprehensive review published in JAMA concluded that CBT is the psychotherapy with the strongest evidence base for anxiety disorders. Across meta-analyses, CBT demonstrated significant efficacy compared with psychological or pill placebo, with effect sizes ranging from small-to-medium for panic disorder (Hedges g = 0.39) and social anxiety disorder (g = 0.41) to a large effect for generalized anxiety disorder (g = 1.01). The review also noted that exposure-based interventions, a core component of CBT for many anxiety disorders, produced large treatment effects compared with control conditions (g = 0.78). Importantly, treatment gains were generally maintained during follow-up periods extending to approximately 12 months, supporting the durability of CBT's clinical benefits and reinforcing its role as a first-line treatment for anxiety disorders (Szuhany & Simon, 2022).
In a large unified series of meta-analyses published in JAMA Psychiatry, Cuijpers et al. (2025) synthesized evidence from 375 randomized controlled trials (423 comparisons) involving 32,968 patients to evaluate the effectiveness of CBT across 10 major mental disorders. CBT was associated with significant symptom reductions across all disorders examined, with effect sizes generally ranging from 0.5 to 1.0 for panic disorder, social anxiety disorder, generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and binge-eating disorder. Even larger effects (g >1.0) were observed for post-traumatic stress disorder (PTSD) and specific phobias. The authors further reported that effect sizes were largest in studies using waitlist controls and more modest in trials comparing CBT with care-as-usual, highlighting the importance of comparator selection when interpreting treatment effects. Overall, the findings support CBT as a first-line intervention across a broad range of psychiatric conditions, although the authors noted variability in study quality and risk of bias across the evidence base.
Depression
NIMH Treatment of Depression Collaborative Research Program (TDCRP) was a landmark multisite randomized controlled trial (RCT) compared Cognitive Behavioral Therapy (CBT), interpersonal therapy (IPT), imipramine plus clinical management, and placebo plus clinical management for major depression. It established that both CBT and IPT were effective treatments, though it also raised important questions about treatment specificity. Subsequent analyses showed that both therapies, as actually practiced, strongly resembled the CBT prototype, and the most consistent predictors of therapeutic gain were the quality of the therapeutic relationship and patients' pretreatment personality dimensions rather than the specific therapy type.
In a randomized clinical trial, Driessen et al. (2013) compared 16 sessions of manualized cognitive behavioral therapy (CBT) with short-term psychodynamic supportive psychotherapy in 341 adult outpatients with major depressive disorder. The investigators hypothesized that psychodynamic therapy would be noninferior to CBT and found no statistically significant differences between treatments across primary outcome measures, remission rates, or one-year follow-up outcomes. Although psychodynamic therapy demonstrated efficacy comparable to CBT, the overall remission rate at post-treatment was relatively modest at approximately 22.7%, indicating that a substantial proportion of patients remained symptomatic despite treatment. The findings strengthened the evidence base supporting short-term psychodynamic therapy as an evidence-based treatment for depression while also highlighting the clinical reality that many patients may require longer duration therapy, combined treatment approaches, or additional interventions to achieve remission.
Weitz et al. (2015) conducted an individual patient data (IPD) meta-analysis to address the longstanding question of whether antidepressant medication is superior to CBT for patients with more severe depression. The investigators pooled primary data from 16 randomized trials involving 1,700 outpatients (794 treated with CBT and 906 treated with antidepressant medication). Using mixed-effects modeling, they examined whether baseline depression severity moderated treatment outcomes. Contrary to earlier interpretations of the NIMH Treatment of Depression Collaborative Research Program and some guideline recommendations favoring medication for severe depression, the analysis found that baseline depression severity did not significantly influence the relative effectiveness of CBT versus pharmacotherapy on symptom reduction, response, or remission outcomes. These results suggest that CBT remains a viable first-line treatment even for individuals with severe depression and challenge the assumption that increasing symptom severity necessarily warrants preferential use of antidepressant medication.
Cuijpers and colleagues (2021) conducted the largest network meta-analysis of psychotherapies for adult depression to date, synthesizing data from 331 randomized controlled trials involving 34,285 patients. The analysis compared CBT, interpersonal psychotherapy (IPT), psychodynamic therapy, behavioral activation, problem-solving therapy, life-review therapy, third-wave therapies, and non-directive supportive counseling. All major psychotherapy modalities demonstrated significantly greater efficacy than care-as-usual and waitlist controls, with standardized mean differences ranging from −0.32 to −0.81, indicating clinically meaningful reductions in depressive symptoms. Importantly, no significant efficacy differences were observed among the established psychotherapies, suggesting broadly comparable effectiveness across treatment approaches. The only exception was non-directive supportive counseling, which was significantly less effective than the other psychotherapies. These findings support multiple evidence-based psychotherapy options for depression and suggest that treatment selection may be guided by patient preference, clinician expertise, and availability rather than superiority of any single modality.
Post-Traumatic Stress Disorder (PTSD)
Trauma-focused CBT (including prolonged exposure and cognitive processing therapy) is the best-supported psychological intervention for PTSD. An NEJM review noted that specific protocols can be divided into exposure therapies (e.g., prolonged exposure) and nonexposure therapies (e.g., cognitive processing therapy), with critical reviews and treatment guidelines emphasizing the relative advantage of CBT-based approaches. EMDR (eye-movement desensitization and reprocessing) is also well-supported. Notably, "branded" interventions share many common components including psychoeducation, emotion regulation, cognitive processing, and meaning-making.
Substance Use Disorders
Project MATCH (1997) was an 8-year, multisite clinical trial sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) that compared cognitive behavioral therapy (CBT), motivational enhancement therapy (MET, 4 sessions), and 12-step facilitation (TSF) for alcohol use disorder. All three interventions produced substantial and durable reductions in alcohol consumption, with minimal evidence that patient characteristics reliably predicted differential treatment response. Importantly, MET achieved outcomes comparable to CBT and TSF despite requiring only 4 sessions versus 12 sessions for the other approaches, supporting its efficiency as a treatment modality.
A systematic review evaluating CBT according to American Psychological Association (APA) Tolin Criteria for empirically supported treatments found that CBT produced small to moderate reductions in substance use compared with inactive control conditions, with the greatest benefits observed during early follow-up periods of 1 to 6 months. Based on treatment efficacy, quality of evidence, and demonstrated effectiveness across diverse populations and substance use disorders, CBT received a strong recommendation as an empirically supported treatment.
Motivational interviewing, initially described by Miller (1983) and subsequently developed by Miller and Rollnick, has a substantial evidence base supporting its use in substance use disorders. A 2023 Cochrane review of 34 studies demonstrated a small to moderate reduction in substance use compared with no intervention, with a standardized mean difference of 0.48 immediately following treatment; however, treatment effects generally attenuated over longer follow-up periods.
Contingency management (CM) emerged from behavioral reinforcement research conducted at Johns Hopkins University in the 1960s-70s and was later formalized through Higgins' voucher-based and Petry's prize-draw models. Evidence from a meta-review demonstrated moderate treatment effects for opioid use disorder and smaller but clinically meaningful benefits for stimulant use disorders. CM has shown effectiveness across a variety of patient populations and treatment settings and is increasingly being adapted to digital delivery platforms to improve accessibility and implementation.
In a meta-review synthesizing findings from 23 meta-analyses comprising 78 effect sizes, psychosocial interventions for substance use disorders were found to provide, at most, moderate short-term benefits compared with inactive controls. The strongest evidence supported combined CBT and motivational interviewing approaches for alcohol and cannabis use disorders, while contingency management demonstrated the most robust support for opioid and stimulant use disorders, highlighting differential treatment strengths across substance categories (Dellazizzo et al., 2023).
Co-Occurring Mental Health and Substance Use Disorders
Integrated treatment models, where the same clinicians provide coordinated mental health and substance use treatment, have generally shown better outcomes than parallel or sequential treatment of each condition alone. A 2026 umbrella review of 28 systematic reviews confirmed that integrated approaches were usually superior to treating one condition alone, though heterogeneity precluded recommending one specific intervention type over another.
The Cochrane review on dual diagnosis (Hunt et al., 2019) emphasized that integrated treatment is a long-term process requiring assertive community outreach, staged interventions, and adherence to an integrated team philosophy.
In general, there is limited evidence in noting which individual psychotherapy to choose, and it should be based upon individual patient needs. The VA/DoD Clinical Practice Guidelines recommend offering a menu of evidence-based psychotherapies including CBT, IPT, behavioral activation, ACT, problem-solving therapy, and short-term psychodynamic psychotherapy to patients, using shared decision-making, as no single therapy has demonstrated clear superiority over others.
Psychotherapy Modalities
Acceptance and Commitment Therapy (ACT)
Acceptance and Commitment Therapy is a mindfulness- and values-based behavioral intervention that targets psychological flexibility rather than direct disputation of symptoms or cognitions. ACT uses acceptance, cognitive defusion, present-moment awareness, self-as-context, values clarification, and committed action to help individuals engage in meaningful behavior despite distressing thoughts, emotions, pain, or trauma-related symptoms. It has transdiagnostic applicability and is commonly used for depression, anxiety disorders, obsessive-compulsive symptoms, chronic pain, and stress-related conditions. The evidence base supports ACT as more effective than passive or usual-care controls for several mental and physical health conditions, although condition-specific evidence strength varies and, for some indications, ACT should be considered an evidence-supported option rather than the most established first-line psychotherapy. A meta-analysis of 39 randomized trials found ACT superior to control conditions and not significantly different from established treatments such as CBT across mixed clinical conditions (A-Tjak et al., 2015).
Behavioral Activation
Behavioral Activation is a structured, behavioral treatment for depression that targets avoidance, withdrawal, and loss of environmental reinforcement. Rather than emphasizing cognitive restructuring as the central mechanism, BA focuses on activity monitoring, values-consistent goal setting, graded task assignment, and reduction of avoidance patterns. A landmark dismantling trial showed that the behavioral activation component of CBT was comparable to the full CBT package, challenging the assumption that cognitive restructuring was required for antidepressant benefit (Jacobson et al., 1996). Subsequent evidence demonstrated that BA was comparable to antidepressant medication and superior to CBT among more severely depressed patients in one major trial, supporting BA as a parsimonious and disseminable treatment option (Dimidjian et al., 2006). Cochrane evidence further supports BA as an effective depression intervention, with particular relevance in settings where brief, structured, and scalable psychotherapy is needed (Uphoff et al., 2020).
Cognitive Behavioral Therapy (CBT)
Cognitive Behavioral Therapy is a structured, time-limited, skills-based psychotherapy that targets maladaptive cognitions, behaviors, and emotional responses. For depression, CBT is grounded in Beck’s cognitive model, including the cognitive triad of negative views of the self, world, and future, and commonly incorporates cognitive restructuring, behavioral activation, problem solving, relapse prevention, and skills rehearsal (Beck, 1979, 2020). The evidence base for CBT in depression is extensive. A large meta-analysis of 409 randomized controlled trials involving 52,702 patients found moderate-to-large effects versus control conditions, with persistence of benefit at 6 to 12 months and longer-term superiority over pharmacotherapy in follow-up comparisons (Cuijpers et al., 2023). Network meta-analytic evidence suggests CBT is broadly comparable to other bona fide psychotherapies for depression, with active therapies generally outperforming care-as-usual (Cuijpers et al., 2021). CBT is also strongly supported across anxiety disorders, OCD, PTSD, panic disorder, insomnia, chronic pain, and eating disorders, with disorder-specific adaptations such as exposure, cognitive restructuring, and response prevention incorporated as clinically indicated (Cuijpers et al., 2025; Szuhany and Simon, 2022; Craske and Stein, 2016).
Cognitive Processing Therapy (CPT)
Cognitive Processing Therapy is a trauma-focused cognitive therapy developed for PTSD. CPT targets trauma-related “stuck points,” including maladaptive beliefs about safety, trust, power/control, esteem, and intimacy. Foundational trials established CPT as effective for PTSD, initially in sexual assault survivors, and later dismantling work showed that the cognitive-only version without a written trauma account was similarly effective, supporting a more streamlined protocol (Resick et al., 2002, 2008). In the largest head-to-head comparison of leading PTSD psychotherapies among veterans, prolonged exposure was statistically more effective than CPT, but the difference did not meet the prespecified threshold for clinical significance; both treatments produced meaningful improvement, supporting shared decision-making and patient preference (Schnurr et al., 2022). The 2023 VA/DoD guideline recommends CPT, EMDR, and PE as the most effective PTSD psychotherapies.
Dialectical Behavior Therapy (DBT)
Dialectical Behavior Therapy is a comprehensive cognitive-behavioral treatment originally developed for chronically suicidal individuals with borderline personality disorder. DBT integrates acceptance and change strategies through individual therapy, group skills training, between-session coaching, and therapist consultation. Core skills include mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness. The original randomized trial demonstrated that DBT reduced parasuicidal behavior, improved retention, and markedly reduced inpatient days compared with treatment-as-usual (Linehan et al., 1991). A later trial showed DBT was superior to community treatment by experts for reducing suicide attempts, medical severity of attempts, psychiatric hospitalization, and emergency department use (Linehan et al., 2006). Cochrane evidence indicates DBT improves BPD severity, self-harm, and psychosocial functioning, although effect sizes vary by comparator and outcome (Stoffers-Winterling et al., 2022).
Exposure-Based Therapy
Exposure-based therapies are structured interventions that systematically and repeatedly expose individuals to feared internal or external stimuli in a controlled and therapeutic manner. The goal is to reduce avoidance, facilitate new learning, and weaken maladaptive fear associations. Emotional processing theory proposed that exposure requires activation of the fear structure and incorporation of corrective information, providing the theoretical foundation for prolonged exposure for PTSD and exposure and response prevention for OCD (Foa and Kozak, 1986). Exposure-based interventions have strong empirical support for anxiety disorders, panic disorder, specific phobia, social anxiety disorder, OCD, and PTSD. Reviews confirm large effects for exposure-based approaches compared with control conditions, particularly when exposure is disorder-specific and delivered with adequate dose and fidelity (Foa and McLean, 2015; Szuhany and Simon, 2022).
Eye Movement Desensitization and Reprocessing (EMDR)
Eye Movement Desensitization and Reprocessing is a trauma-focused psychotherapy that uses an eight-phase protocol combining trauma memory activation with bilateral stimulation, most commonly guided eye movements. EMDR aims to reduce distress associated with traumatic memories and facilitate adaptive reprocessing of trauma-related beliefs and affect. Shapiro’s original controlled study introduced EMDR as a treatment for traumatic memories (Shapiro, 1989). A network meta-analysis of PTSD psychotherapies found EMDR had one of the largest effects versus waitlist and showed sustained benefit at follow-up, along with trauma-focused CBT (Mavranezouli et al., 2020). Current VA/DoD guidance identifies EMDR, CPT, and PE as the most effective and recommended trauma-focused psychotherapies for PTSD
Interpersonal Psychotherapy (IPT)
Interpersonal Psychotherapy is a structured, time-limited psychotherapy that conceptualizes depressive symptoms within the context of current interpersonal functioning. IPT focuses on four primary problem areas: grief, role disputes, role transitions, and interpersonal deficits. The original manual established IPT as a practical, diagnosis-focused model for depression (Klerman and Weissman, 1984). Meta-analytic evidence demonstrates a large effect of IPT versus control conditions, with no significant difference from other psychotherapies, and evidence that maintenance IPT combined with pharmacotherapy reduces relapse risk (Cuijpers et al., 2011). A later comprehensive meta-analysis confirmed moderate-to-large effects for acute depression and no significant difference from other psychotherapies or pharmacotherapy (Cuijpers et al., 2016). Individual patient data meta-analysis found no significant difference between IPT and antidepressants for post-treatment depression or social functioning (Cohen et al., 2024).
Mentalization-Based Treatment (MBT)
Mentalization-Based Treatment is a psychodynamic and attachment-informed psychotherapy developed primarily for borderline personality disorder. MBT aims to improve the patient’s capacity to understand one’s own and others’ mental states, particularly during emotionally intense interpersonal interactions. Bateman and Fonagy’s clinical trials established MBT as effective for BPD, including reductions in self-harm, depression, and social dysfunction, with sustained long-term benefit in follow-up studies (Bateman and Fonagy, 1999, 2001, 2008, 2009). Pooled Cochrane data from five randomized trials showed MBT was associated with reductions in self-harm and suicidal behavior compared with treatment-as-usual, supporting MBT as an evidence-based option for BPD when delivered in a structured model with trained clinicians (Stoffers-Winterling et al., 2022).
Psychodynamic Psychotherapy
Psychodynamic psychotherapy focuses on unconscious processes, affect regulation, internal conflict, defense mechanisms, developmental experiences, and recurring interpersonal patterns. Treatment uses the therapeutic relationship, including transference and countertransference, to increase insight and modify maladaptive relational and emotional patterns. For depression and personality disorders, psychodynamic approaches may be delivered in short-term or longer-term formats depending on complexity and clinical need. Meta-analytic evidence indicates that psychodynamic therapy is equivalent to other treatments of established efficacy for target symptoms at post-treatment and follow-up when tested using formal equivalence methods (Steinert et al., 2017). Evidence in BPD also supports psychodynamic approaches, although durability and study quality limitations should be considered in medical policy interpretation (Leichsenring et al., 2023).
Psychotherapy vs. Pharmacotherapy
For major depressive disorder, psychotherapy and pharmacotherapy are both evidence-based treatments, with combined treatment often producing superior outcomes compared with either modality alone. The NIMH Treatment of Depression Collaborative Research Program found no significant differences among CBT, IPT, imipramine plus clinical management, and placebo plus clinical management at termination, although IPT and CBT showed advantages in some longer-term patient-reported domains such as interpersonal relationships and understanding of depression (Elkin et al., 1989). A network meta-analysis of 101 randomized trials found no difference between psychotherapy alone and pharmacotherapy alone, but combined treatment was superior to either modality alone and was more acceptable than pharmacotherapy alone (Cuijpers et al., 2020). For PTSD, current VA/DoD guidance recommends individual trauma-focused psychotherapies over pharmacologic interventions for PTSD treatment, with PE, CPT, and EMDR identified as the most effective PTSD psychotherapies. [ptsd.va.gov], [healthquality.va.gov]
Schema-Focused Therapy (SFT)
Schema-Focused Therapy is an integrative psychotherapy combining cognitive-behavioral, attachment, experiential, and psychodynamic elements. It targets maladaptive schemas and schema modes that contribute to chronic personality pathology, especially borderline personality disorder. In a landmark head-to-head randomized trial comparing SFT with transference-focused psychotherapy over three years, SFT produced greater improvement in BPD severity and lower dropout rates, supporting its role as an effective longer-term treatment model (Giesen-Bloo et al., 2006). More recent multicenter evidence comparing DBT and SFT found no significant between-treatment differences across outcomes, with large improvements in both groups over three years, supporting either modality as a reasonable evidence-based option when delivered with adequate fidelity and patient engagement (Wibbelink et al., 2026).
Short-Term Psychodynamic Psychotherapy (STPP)
Short-Term Psychodynamic Psychotherapy is a focused, time-limited psychodynamic treatment that targets circumscribed conflicts, affective patterns, interpersonal difficulties, and maladaptive defenses. For depression, STPP has evidence of benefit compared with control conditions and appears broadly comparable with other active psychotherapies. A meta-analysis update of 54 studies involving 3,946 patients found STPP significantly more effective than control conditions, with no significant differences from other psychotherapies at post-treatment or follow-up (Driessen et al., 2015). An equivalence meta-analysis comparing psychodynamic therapy with treatments of established efficacy found psychodynamic therapy equivalent for target symptoms at post-treatment and follow-up using a rigorous two one-sided test procedure (Steinert et al., 2017). For OCD, emerging RCT evidence suggests STPP may benefit patients who cannot tolerate exposure-based approaches, but this evidence remains substantially less mature than ERP or CBT evidence (Leichsenring et al., 2026).
Transference-Focused Psychotherapy (TFP)
Transference-Focused Psychotherapy is a manualized psychodynamic treatment for borderline personality disorder that focuses on identity integration, object relations, affective dysregulation, and maladaptive interpersonal patterns as they emerge in the therapeutic relationship. In a randomized comparison of TFP, DBT, and supportive psychotherapy, all three treatments improved outcomes, but TFP was uniquely associated with improvement across domains including reflective functioning and attachment organization, in addition to suicidality and anger (Clarkin et al., 2007). A subsequent trial found TFP superior to community treatment for BPD severity, although the evidence base remains smaller than that for DBT and MBT (Doering et al., 2010). TFP is therefore best characterized as an established but less extensively studied psychotherapy for BPD relative to DBT and MBT (Bohus et al., 2021).
Trauma-Focused Therapies
Trauma-focused therapies are psychotherapies that directly address traumatic memories, trauma-related beliefs, avoidance, hyperarousal, and emotional dysregulation. They include prolonged exposure, CPT, EMDR, trauma-focused CBT, and related structured treatments. Major reviews identify trauma-focused CBT and EMDR as effective interventions for PTSD, with evidence that both outperform non-trauma-focused approaches at short-term follow-up (Bisson et al., 2013). NEJM review evidence emphasizes that trauma-focused CBT is among the best-supported psychological interventions for PTSD and that branded trauma interventions share common therapeutic components such as psychoeducation, emotion regulation, cognitive processing, and meaning-making (Shalev et al., 2017). The 2023 VA/DoD guideline recommends PE, CPT, and EMDR as first-line trauma-focused psychotherapies and suggests Ehlers’ cognitive therapy, present-centered therapy, and WET as alternatives with sufficient evidence.
Written Exposure Therapy (WET)
Written Exposure Therapy is a brief trauma-focused psychotherapy for PTSD consisting of five sessions, typically involving structured writing about the traumatic event without extensive between-session homework. WET is designed to reduce trauma-related avoidance and facilitate emotional processing in a lower-burden format than many standard PTSD protocols. Randomized trials demonstrated that WET was noninferior to CPT and noninferior to PE, with fewer dropouts, supporting WET as a clinically meaningful and efficient PTSD treatment option (Sloan et al., 2018, 2023). VA/DoD guidance identifies WET as a suggested effective psychotherapy for PTSD, though PE, CPT, and EMDR remain the strongly recommended first-line trauma-focused psychotherapies.
Appendix
Individual Psychotherapy and Provider Qualifications
Individual therapy may only be provided by licensed behavioral health professionals, which include psychiatrists, psychologists, licensed clinical social workers, licensed professional counselors, licensed marriage and family therapists, licensed chemical dependency counselors, psychiatric nurse practitioners, and physician assistants or associates with psychiatric training. It is important to note that non-behavioral health providers are not trained or licensed to provide psychotherapy. The entire architecture of psychotherapy research, training science, licensing law, and patient safety evidence converges on the conclusion that effective and safe psychotherapy delivery requires specific mental health education, supervised clinical training in evidence-based treatments, ongoing supervision, and appropriate licensure—none of which are components of other non-behavioral health professional training.
Unlicensed or provisionally licensed clinicians may provide therapy only under the direct supervision of a licensed provider, in compliance with state and federal regulations. Direct supervision means that a licensed and credentialed behavioral health professional is responsible for overseeing and guiding the clinical work of the unlicensed or provisionally licensed clinician and is physically present on-site and immediately accessible to the clinician. The licensed supervisor holds the ultimate responsibility for the quality of care, all clinical decision-making, co-signing clinical documentation, and the conduct of the individual therapy session.
Supervision and supervisee ratios are regulated by state laws and regulations, which can vary significantly across jurisdictions. However, many professional organizations and sources recommend that a supervisor should not oversee more than 6 supervisees at a time. This guideline is based on the understanding that maintaining a manageable number of supervisees allows for more effective supervision, ensuring that each supervisee receives adequate attention, support, and feedback necessary for their professional development. Adhering to these recommended ratios is crucial for fostering a productive supervisory relationship and enhancing the overall quality of clinical training.
Documentation Requirements
All documentation should be individualized for each member and each psychotherapy session. While technology is a helpful aid, overreliance on copy/paste or carry forward features of an electronic medical record can lead to duplication of clinical information and the appearance of identical claim/documentation submission which could affect payer reimbursement for services. While each of the following may not be appropriate for each individual encounter, the medical record should have clear documentation that captures the following data and follows the member’s progression through treatment.
| Documentation Section / Domain | Content |
| Session Information |
|
| Clinical/Session Content |
|
| Assessment and Treatment Planning |
|
| Outcome Measures (as applicable) |
Use of standardized tools/measurement-based care (e.g., PHQ-9, GAD-7)
|
| Collaboration and Coordination (as applicable) |
|
| Compliance and Legal Elements |
|
| Billing and Coding Accuracy |
|
Billing and Reimbursement
For psychotherapy billing with concurrent evaluation and management(E/M) services, add-on codes should be utilized. Psychotherapy CPT codes are time-based, so total time spent in individual psychotherapy must be documented. Additionally, documentation should demonstrate that the psychotherapy and E/M services are separately identifiable. Add-on codes of 90833, 90836, or 90838 with other psychotherapy prolonged services codes are not permitted. Note: The following coding discussion is considered supplemental to the CPT Codes / HCPCS Codes / ICD-10 Codes section that includes code descriptions and codes considered covered or not covered.
| CPT Code | Time / Requirements |
| 90832 | Psychotherapy: 16-37 minutes, face-to-face |
| 90833 | Psychotherapy: 16-37 minutes, face-to-face, with E/M service |
| 90834 | Psychotherapy: 38-52 minutes, face-to-face |
| 90835 | Psychotherapy: 38-52 minutes, face-to-face, with E/M service. |
| 90836 | Psychotherapy: 53 or more minutes, face-to-face |
| 90837 | Psychotherapy: 53 or more minutes, face-to-face, with E/M service |
| 90839 |
Psychotherapy for crisis; first 60 minutes *Billed for the first 60 minutes of psychotherapy for a patient in crisis, and add-on code 90840 billed for each additional 30 minutes |
| 90840 |
Psychotherapy for crisis; each additional 30 minutes (list separately in addition to code for primary service) |
Quality Indicators, Continued Treatment, and Ending Therapy Guidelines
Quality individual psychotherapy is characterized by several key indicators that ensure effective treatment and positive outcomes for patients. First and foremost, accurate diagnosis is essential, as it lays the foundation for appropriate treatment. Evidence-based treatment selection is crucial, ensuring that the chosen interventions are supported by research and proven to be effective. Individualized treatment planning is also important, as it tailors the therapeutic approach to meet the unique needs of each patient. Timely access to care is necessary to address issues promptly and prevent deterioration of the patient's condition. Additionally, appropriate treatment intensity must be maintained to match the severity of the patient's symptoms and needs.
Ongoing assessment of symptoms and functional improvement is vital for tracking progress and making necessary adjustments to the treatment plan. Coordination with primary care and other treating clinicians, when appropriate, enhances the overall care experience and ensures comprehensive support for the patient. The appropriate use of validated outcome measures helps in evaluating the effectiveness of the therapy. Safe management of suicide risk and other clinical emergencies is a critical component of quality care, ensuring that patients are protected during vulnerable times. Furthermore, patient-centered and culturally responsive care is essential to address the diverse backgrounds and preferences of patients. Finally, appropriate discharge planning and relapse prevention strategies are necessary to support patients as they transition out of therapy and maintain their progress.
Continued Treatment
Continued psychotherapy is deemed medically necessary when documentation demonstrates specific criteria. Persistent symptoms or functional impairment indicate that the patient continues to require therapeutic support. Additionally, measurable progress toward treatment goals or a reasonable expectation of improvement justifies the continuation of therapy. If progress is limited, modification of treatment interventions should be considered to better meet the patient's needs. Furthermore, there must be a continued need for skilled therapeutic intervention that cannot be effectively provided through less intensive services, ensuring that the patient receives the appropriate level of care.
Discharge Criteria
Discharge from psychotherapy should be considered when one or more specific criteria are met. Treatment goals must have been substantially achieved, indicating that the patient has made significant progress. Symptoms should have remitted or significantly improved, demonstrating the effectiveness of the therapy. The patient must also show sustained functional improvement, reflecting their ability to manage daily life effectively. If a lower level of care is clinically appropriate, discharge may be warranted. Additionally, if the patient declines treatment despite being educated about the risks and benefits, or if continued psychotherapy is no longer medically necessary, discharge should be considered. These criteria ensure that the decision to discharge is made thoughtfully and in the best interest of the patient's ongoing health and well-being.
References
The above policy is based on the following references:
- Ablon JS, Jones EE. Validity of controlled clinical trials of psychotherapy: Findings from the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 2002;159(5):775-783.
- American Professional Agency. Documentation for mental health professionals: Key ethical standards and risk management strategies [website]. 2025. Available at: https://www.americanprofessional.com/wp-content/uploads/APA-All-Professions-Handout_Documentation_Summer-2025.pdf?x21833. Accessed August 12, 2026.
- Arntz A, Jacob GA, Lee CW, et al. Effectiveness of predominantly group schema therapy and combined individual and group schema therapy for borderline personality disorder: A randomized clinical trial. JAMA Psychiatry. 2022;79(4):287-299.
- Beck JS. Cognitive behavior therapy: Basics and beyond. 3rd ed. Guilford Press; 2020.
- BehaveHealth. Mastering mental health progress notes: A comprehensive guide to best practices, compliance, and effective documentation [website]. Available at: https://behavehealth.com/progress-notes. Accessed August 12, 2026.
- Bernard JM, Goodyear RK. Fundamentals of clinical supervision. 5th ed. Pearson; 2014.
- Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;2013(12):CD003388.
- Blatt SJ, Zuroff DC. Empirical evaluation of the assumptions in identifying evidence based treatments in mental health. Clin Psychol Rev. 2005;25(4):459-486.
- Blatt S, Zuroff D, Bondi C, Sanislow C. Short- and long-term effects of medication and psychotherapy in the brief treatment of depression: Further analyses of data from the NIMH TDCRP. Psychother Res. 2000;10(2):215-234.
- Bohus M, Stoffers-Winterling J, Sharp C, et al. Borderline personality disorder. Lancet. 2021;398(10310):1528-1540.
- Boness CL, Votaw VR, Schwebel FJ, et al. An evaluation of cognitive behavioral therapy for substance use disorder: A systematic review and application of the Society of Clinical Psychology criteria for empirically supported treatments. Clin Psychol (New York). 2023;30(2):129-142.
- Burden J, Hagedorn H, Liberto J, et al. VA/DoD clinical practice guideline for the management of substance use disorders: Provider summary, Version 4.0. 2021. Available at: https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGProviderSummary.pdf. Accessed August 12, 2026.
- Caldwell D, Hunot V, Moore TH, et al. Behavioural therapies versus treatment as usual for depression. Cochrane Database Syst Rev. 2010;(9):CD008697.
- Centers for Disease Control and Prevention (CDC). Documentation matters fact sheet for behavioral health practitioners [website]. December 1, 2015. Available at: https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-program/education/resource-library/documentation-matters-fact-sheet-behavioral-health-practitioners. Accessed August 12, 2026.
- Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD): Psychiatric diagnostic evaluation and psychotherapy services (L33252). July 1, 2020. Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33252. Accessed August 12, 2026.
- Ciharova M, Furukawa TA, Efthimiou O, et al. Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: A network meta-analysis. J Consult Clin Psychol. 2021;89(6):563-574.
- Cohen D, Lau K, Lau S. Effect of psychotherapy on patients with borderline personality disorder. Am Fam Physician. 2022;106(4):381-382.
- Cohen ZD, Breunese J, Markowitz JC, et al. Comparative efficacy of interpersonal psychotherapy and antidepressant medication for adult depression: A systematic review and individual participant data meta-analysis. Psychol Med. 2024;54(14):3785-3794.
- Craske MG, Stein MB. Anxiety. Lancet. 2016;388(10063):3048-3059.
- Cuijpers P, Donker T, Weissman MM, et al. Interpersonal psychotherapy for mental health problems: A comprehensive meta-analysis. Am J Psychiatry. 2016;173(7):680-687.
- Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: A meta-analysis. Am J Psychiatry. 2011;168(6):581-592.
- Cuijpers P, Harrer M, Miguel C, et al. Cognitive behavior therapy for mental disorders in adults: A unified series of meta-analyses. JAMA Psychiatry. 2025;82(6):563-571.
- Cuijpers P, Miguel C, Harrer M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105-115.
- Cuijpers P, Miguel C, Harrer M, et al. Psychological treatment of depression: A systematic overview of a 'Meta-Analytic Research Domain'. J Affect Disord. 2023;335:141-151.
- Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92-107.
- Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: A network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry. 2021;20(2):283-293.
- Dellazizzo L, Potvin S, Giguère S, et al. Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders. Psychiatry Res. 2023;326:115318.
- Driessen E, Hegelmaier LM, Abbass AA, et al. The efficacy of short-term psychodynamic psychotherapy for depression: A meta-analysis update. Clin Psychol Rev. 2015;42:1-15.
- Driessen E, Van HL, Don FJ, et al. The efficacy of cognitive-behavioral therapy and psychodynamic therapy in the outpatient treatment of major depression: A randomized clinical trial. Am J Psychiatry. 2013;170(9):1041-1050.
- Emmelkamp PM, David D, Beckers T, et al. Advancing psychotherapy and evidence-based psychological interventions. Int J Methods Psychiatr Res. 2014;23 Suppl 1(Suppl 1):58-91.
- Falender CA, Shafranske EP. Clinical supervision: A competency-based approach. American Psychological Association; 2004.
- Foa EB, McLean CP. The efficacy of exposure therapy for anxiety-related disorders and its underlying mechanisms: The case of OCD and PTSD. Annu Rev Clin Psychol. 2016;12:1-28.
- Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. Am J Psychiatry. 2021;178(1):17-29.
- Grant JE. Clinical practice: Obsessive-compulsive disorder. N Engl J Med. 2014;371(7):646-653.
- Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: Advances in diagnosis and treatment. JAMA. 2017;317(13):1358-1367.
- Holloway EL. Supervision: A review of the literature. J Couns Dev. 1995;73(5):509-515.
- Holloway EL, Wampold BE. Effects of supervision on the therapeutic alliance: A meta-analysis. Psychotherapy. 1990;27(2):227-234.
- Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2019;12(12):CD001088.
- ICANotes. Behavioral health documentation best practices. 2023.
- Juul S, Jakobsen JC, Jørgensen CK, et al. The difference between shorter- versus longer-term psychotherapy for adult mental health disorders: A systematic review with meta-analysis. BMC Psychiatry. 2023;23(1):438.
- Knekt P, Heinonen E, Härkäpää K, et al. Randomized trial on the effectiveness of long- and short-term psychotherapy on psychosocial functioning and quality of life during a 5-year follow-up. Psychiatry Res. 2015;229(1-2):381-388.
- Knekt P, Virtala E, Härkänen T, et al. The outcome of short- and long-term psychotherapy 10 years after start of treatment. Psychol Med. 2016;46(6):1175-1188.
- Ladany N, Hill CE, Corbett MM, et al. Supervisee attachment, supervisory working alliance, and supervisee satisfaction. J Couns Psychol. 1996;43(3):292-299.
- Leiba L. Psychotherapy documentation tips from an auditor. American Academy of Professional Coders (AAPC). September 1, 2021. Available at: https://www.aapc.com/blog/81898-psychotherapy-documentation-tips-from-an-auditor/. Accessed August 12, 2026.
- Leichsenring F, Heim N, Leweke F, et al. Borderline psychodynamic therapy of obsessive-compulsive disorder: A randomized controlled trial of unmedicated patients. Psychother Psychosom. 2026 Jan 9 [Online ahead of print].
- Leichsenring F, Heim N, Leweke F, et al. Borderline personality disorder: A review. JAMA. 2023;329(8):670-679.
- Linehan MM. DBT Skills Training Manual. 2nd ed. Guilford Press; 2015.
- Maljanen T, Knekt P, Lindfors O, et al. The cost-effectiveness of short-term and long-term psychotherapy in the treatment of depressive and anxiety disorders during a 5-year follow-up. J Affect Disord. 2016;190:254-263.
- Markussen HV, Aasdahl L, Viksveen P, et al. A treatment strategy for meeting life as it is. Patients' and therapists' experiences of brief therapy in a district psychiatric centre: A qualitative study. PLoS One. 2021;16(10):e0258990.
- Mavranezouli I, Megnin-Viggars O, Daly C, et al. Psychological treatments for post-traumatic stress disorder in adults: A network meta-analysis. Psychol Med. 2020;50(4):542-555.
- McQuaid JR, Buelt A, Capaldi V, et al. The management of major depressive disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2022;175(10):1440-1451.
- Mootz JJ, Mufson L, Chiao S, Weissman M. Interpersonal psychotherapy for the treatment of depression among adults and adolescents. Annu Rev Clin Psychol. 2026;22(1):309-341.
- O'Connell B, Dowling M. Dialectical behaviour therapy (DBT) in the treatment of borderline personality disorder. J Psychiatr Ment Health Nurs. 2014;21(6):518-525.
- Parker G, Fletcher K. Treating depression with the evidence-based psychotherapies: A critique of the evidence. Acta Psychiatr Scand. 2007;115(5):352-359.
- Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914-927.
- Perry C, Liberto J, Milliken C, et al. The management of substance use disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2022;175(5):720-731.
- Robinson L, Kellett S, Delgadillo J. Dose-response patterns in low and high intensity cognitive behavioral therapy for common mental health problems. Depress Anxiety. 2020;37(3):285-294.
- Rupp C, Doebler P, Ehring T, Vossbeck-Elsebusch AN. Emotional processing theory put to test: A meta-analysis on the association between process and outcome measures in exposure therapy. Clin Psychol Psychother. 2017;24(3):697-711.
- Schnurr PP, Chard KM, Ruzek JI, et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: A randomized clinical trial. JAMA Netw Open. 2022;5(1):e2136921.
- Schnurr PP, Hamblen JL, Wolf J, et al. The management of posttraumatic stress disorder and acute stress disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2024;177(3):363-374.
- Schwenker R, Dietrich CE, Hirpa S, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023;12(12):CD008063.
- Selinheimo S, Gluschkoff K, Kausto J, et al. Psychotherapy duration and work disability: A prospective Finnish register study. Acta Psychiatr Scand. 2024;149(5):415-424.
- Semenya AM, Bhatnagar P. Diagnosis and management of obsessive-compulsive disorder in the primary care setting. Am Fam Physician. 2024;110(4):385-392.
- Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376(25):2459-2469.
- Shefler G, Dasberg H, Ben-Shakhar G. A randomized controlled outcome and follow-up study of Mann's time-limited psychotherapy. J Consult Clin Psychol. 1995;63(4):585-593.
- Shepardson RL, Khan JS, Buckheit KA, Funderburk JS. Treatment of anxiety for adults in primary care settings: A review. JAMA Intern Med. 2026;186(7):878-889.
- Simon GE, Moise N, Mohr DC. Management of depression in adults: A Review. JAMA. 2024;332(2):141-152.
- Simpson EL, Essat M, Wong R, Stacey S, Day E. Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring common mental health disorder: An umbrella review. Drug Alcohol Rev. 2026;45(1):e70066.
- Sloan DM, Marx BP, Acierno R, et al. Written exposure therapy vs prolonged exposure therapy in the treatment of posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry. 2023;80(11):1093-1100.
- Sloan DM, Marx BP, Lee DJ, Resick PA. A brief exposure-based treatment vs cognitive processing therapy for posttraumatic stress disorder: A randomized noninferiority clinical trial. JAMA Psychiatry. 2018;75(3):233-239.
- Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA. 2015;314(5):489-500.
- Steinert C, Munder T, Rabung S, et al. Psychodynamic therapy: As efficacious as other empirically supported treatments? A meta-analysis testing equivalence of outcomes. Am J Psychiatry. 2017;174(10):943-953.
- Stitzer M. Contingency management in the treatment of substance use disorders: A historical narrative. Prev Med. 2026 May 1 [Online ahead of print].
- Szuhany KL, Simon NM. Anxiety disorders: A review. JAMA. 2022;328(24):2431-2445.
- The Joint Commission. Documentation of care, treatment, or services in behavioral health care. 2nd ed. Joint Commission Resources; 2023.
- Uphoff E, Ekers D, Robertson L, et al. Behavioural activation therapy for depression in adults. Cochrane Database Syst Rev. 2020;7(7):CD013305.
- Watkins CE. The importance of supervision in the training of psychotherapists: A review of the literature. Psychotherapy. 2011;48(1):1-10.
- Weitz ES, Hollon SD, Twisk J, et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: An individual patient data meta-analysis. JAMA Psychiatry. 2015;72(11):1102-1109.
- Wibbelink CJM, Kamphuis JH, Sinnaeve R, et al. Dialectical behavior therapy vs schema therapy for patients with borderline personality disorder: The BOOTS multicenter randomized clinical trial. JAMA Psychiatry. 2026;83(7):669-681.
- Zhang A, Franklin C, Jing S, et al. The effectiveness of four empirically supported psychotherapies for primary care depression and anxiety: A systematic review and meta-analysis. J Affect Disord. 2019;245:1168-1186.
